Neoadjuvant pembrolizumab shows promise
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0131-y
Abstract: org/10.1200/JCO.18.01148 (2018) Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC) is the standard-of-care approach for patients with muscle-invasive bladder cancer (MIBC); however, this approach is rarely used owing to poor tolerability. Now, new data from… read more here.
Keywords: chemotherapy; disease; pembrolizumab shows; neoadjuvant pembrolizumab ... See more keywords
KEYNOTE-689: Phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps6090
Abstract: TPS6090 Background: Evidence of efficacy and pathological response at the time of surgery was reported in two phase 2 studies (NCT02296684 and NCT02641093) of preoperative pembrolizumab in patients with high-risk, resectable, locally advanced (LA) head… read more here.
Keywords: soc; cell carcinoma; pembrolizumab; neoadjuvant pembrolizumab ... See more keywords
Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.2520
Abstract: 2520 Background: Pembrolizumab (Pembro), anti-PD1 therapy, is FDA approved for refractory microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) advanced/metastatic solid tumors. The robust activity of anti-PD1 therapy in these tumors argues for a neoadjuvant organ-sparing… read more here.
Keywords: mismatch repair; response; solid tumors; neoadjuvant pembrolizumab ... See more keywords
Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-871
Abstract: Background Pembrolizumab has been shown to be effective and safe in improving the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, the effectiveness and safty of pembrolizumab in the induction treatment of patients… read more here.
Keywords: lung cancer; neoadjuvant pembrolizumab; stage iii; stage ... See more keywords
Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.849984
Abstract: Background In this single-arm study, the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy were evaluated in patients with resectable esophageal squamous cell carcinoma (ESCC). Methods This study included patients with ESCC of clinical stages… read more here.
Keywords: neoadjuvant pembrolizumab; single arm; chemotherapy; arm study ... See more keywords